MDT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

MD

Mkt Cap

$117.85B

Volume

7.11M

Next Earnings

N/A

Chart Financials Earnings News About Dividends Insider Filings

3 Dividend Stocks to Buy and Hold for 10 YearsThe article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.The Motley Fool · Sep 18, 2026

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?Medtronic's stock is down 3% this year despite strong fundamentals, presenting a buying opportunity for growth-oriented investors. The company's Hugo robotic-assisted surgery system is gaining traction and eroding competitor Intuitive Surgical's market dominance. With Q1 FY2027 revenue up 13.7% YoY, raised full-year guidance, a near-Dividend King status (49 consecutive years of dividend increases), and attractive valuation metrics, analysts view the stock as undervalued compared to peers.The Motley Fool · Sep 17, 2026

Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive LandscapeThe global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.GlobeNewswire Inc. · Sep 17, 2026

Medtronic Is on the Cusp of Becoming a Dividend King. Is the Stock a Buy for Income Investors?Medtronic is one year away from achieving Dividend King status with 49 consecutive years of dividend increases. While the company has a healthy 45% payout ratio and appears well-positioned to reach this milestone, its appeal to income investors may be limited due to slow dividend growth rates. The company is balancing dividend increases with investments in growth drivers like robotic surgery and cardiac products, plus the planned divestiture of its MiniMed diabetes business. For investors seeking both income and capital appreciation, Medtronic could be a solid long-term hold if anticipated earnings growth materializes.The Motley Fool · Sep 9, 2026

Medtronic Raises 2027 Outlook as Broad-Based Growth Gains MomentumMedtronic (MDT) raised its fiscal 2027 revenue growth guidance to 7.25%-7.75% following a strong first quarter with adjusted EPS of $1.45 (up 15.1% YoY) and revenues of $9.76 billion (up 13.7%). The company's recent acquisitions in neurovascular and pain markets add exposure to faster-growing segments. However, margin expansion remains challenged by unfavorable product mix and tariff pressures, with management targeting only 50 basis points of improvement.Zacks Investment Research · Sep 9, 2026

Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should BeMedtronic has undergone strategic restructuring by exiting less profitable businesses and investing in new technologies like its Hugo surgical robot. The company reported its highest annual revenue growth in a decade in fiscal 2026, with Q1 FY2027 revenues jumping 13.7% and management raising full-year guidance. With a 3.08% dividend yield and 48-year dividend increase streak, the stock has risen 15% in three months but remains 30% below its 2021 high, suggesting potential upside for dividend investors.The Motley Fool · Sep 9, 2026

Novocure Reports Patient Data Exposure in Cybersecurity IncidentNovocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.Zacks Investment Research · Sep 7, 2026

Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.The Motley Fool · Sep 5, 2026

Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.GlobeNewswire Inc. · Sep 4, 2026

4 Reasons to Buy Medtronic Stock Like There's No TomorrowMedtronic, a major medical device maker, is experiencing a recovery after a 30% decline over five years. The company achieved its strongest revenue growth in a decade (8.4% in fiscal 2026), driven by cardiovascular business expansion. With improving free cash flow, a 3.1% dividend yield, and plans to become a Dividend King, Medtronic trades at a valuation discount (18x forward earnings) compared to peers and the S&P 500.The Motley Fool · Sep 3, 2026

MD

MDTMedtronic plc

MDT

Pay with—

Available Balance0.00

Your PositionYou don't own any MDT yet.

Related Tickers

Earnings

Dividends

Ex Sep 25

Amount$0.72

PaysOct 16

Last · Jun 26Quarterly

Amount$0.72

Yield3.13%

Annual$2.88